News

Learn about real-time information of BJ Bioscience Inc

Cooperation | Kaijie (Suzhou) and Boji biomedicine jointly develop accompanying diagnostic products of tumor targeted therapeutic drugs
2019-09-19 00:00:00
Company diagnostics (CDX) is an in vitro diagnosis (IVD) technology, which can provide information about the safety and effectiveness of patients' drugs for specific treatment, and help to determine the patient groups that can benefit from a certain treatment product, so as to improve the treatment effect, reduce toxic and side effects, and achieve precision medicine. Concomitant diagnosis is an important means to achieve accurate and targeted treatment of tumors. In 2014, the US FDA issued accompanying diagnosis guidelines, requiring that drugs for the treatment of certain diseases must be accompanied by accompanying diagnosis products before they can be put on the market. Although China has not yet issued relevant laws and regulations, the cooperation between diagnostic companies and pharmaceutical enterprises to jointly develop drugs and accompanying diagnostic products has increasingly become one of the mainstream business models. A few days ago, this phenomenon was well confirmed by the wonderful reports of experts in various fields at the China Biological Industry Conference and precision medicine and accompanying diagnosis branch held in Guangzhou on June 11, 2019. Kaijie (Suzhou) translational medicine research Co., Ltd. (hereinafter referred to as "Kaijie (Suzhou)") closely follows the tide of the times, develops and innovates, takes the lead in developing accompanying diagnostic products with a number of pharmaceutical enterprises in China, and has become a leader in the industry.

Boji biomedical technology (Hangzhou) Co., Ltd. (hereinafter referred to as "Boji biomedical"), a cutting-edge pharmaceutical company committed to biomedical research and development and with top technologies at home and abroad, also aims at the trend and market of precision medicine. While developing tumor targeted antibody drugs, it has taken into account the simultaneous joint development of diagnostic products. Recently, Kaijie (Suzhou) and Boji biomedicine have reached a strategic cooperation on the joint development of the concomitant diagnosis of the anti-tumor targeted drug bj-001. The research and development of the targeted drug has now entered the ind application stage. It is expected that in the second half of the year, the United States and China will successively carry out clinical research on patients with high expression of its target cancers such as lung cancer, head and neck cancer and pancreatic cancer.

 

 

对于此次合作,博际生物医药共同创始人兼首席执行官张海洲博士表示:

我们非常高兴能够与实力雄厚的凯杰(苏州)开展合作。通过共同开发高质量的伴随诊断产品,博际生物医药将能够在更精准地入组潜在受益病人和获得更理想数据的同时,实现更科学的试验投入,大幅提升新药的有效性和研发的成功率,从而助力缩短创新抗体药物的整体开发进程。

凯杰(苏州)董事长兼首席执行官张亚飞博士也对此发表评论:

凯杰(苏州)一直以来都秉承“诊断伴随治疗”这一理念服务于广大制药企业,凭借综合的转化医学平台、优秀的团队管理经验和在伴随诊断领域的多年积淀,我们在伴随诊断产品的开发及入组检测方面积攒了大量的成功经验,目前已与多家国内外知名药企建立了良好的合作伙伴关系。我们很高兴能与博际生物医药开展合作,此次合作将为双方未来更广阔的战略合作打下了坚实的基础,并助力共同推动中国精准医疗与伴随诊断协同发展的精准医疗理念。

根据协议,凯杰(苏州)将为博际生物医药肿瘤候选药物BJ-001提供免疫组化检测(IHC)方法的建立并同步共同开发伴随诊断盒。凯杰(苏州)与博际生物医药的强强联合将为中国癌症患者的精准医疗带来新希望。

 

关于博际生物医药

博际生物医药是一家致力于创新药物研发的生物技术公司,是由包括国家“重大新药创制”科技重大专项审评专家在内的、具有多年中外创新药物研发经验的海归专家创建,拥有商业秘密保护的抗体发现平台和国内外顶尖技术,目前主要研发用于肿瘤和感染性疾病的生物药。公司主要科研和管理团队具有多年在国内外研发公司和国家重点科研机构尤其是欧美跨国公司从事抗体类药物研发和管理经验。着眼于研发的全球观和立足于雄厚的资本支持,博际生物医药在创始伊始就从全球的视角对研发进行全球布局,同时拥有美国旧金山和中国杭州两个研发实验室,使公司在创业初期就能实现人才、技术、管理与资本市场的全方位集合,为公司的全球定位和发展奠定了坚实的基础。

 

关于凯杰(苏州)转化医学

凯杰(苏州)是与德国QIAGEN于2013年合资成立的转化医学中心,致力于打造中国最全面、服务能力最强的综合性转化医学服务大平台,建立完善了基因组学、蛋白质组学、细胞组学以及病理组学等先进技术平台,和经验丰富的高素质专业化技术团队,凯杰(苏州)为精准医疗提供生物标志物的发现、验证,新药临床试验病人分子检测和入组筛选,检测方法开发以及伴随诊断试剂盒研发和商业化等一体化解决方案,并为患者提供临床检测用药指导服务,是精准诊断行业整体解决方案的开拓创新者和领导者。